Kane Biotech is trading at 0.0303 as of the 30th of January 2026. This is a 4.11 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0303. Kane Biotech has about a 34 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 1st of November 2025 and ending today, the 30th of January 2026. Click here to learn more.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. The company has 124.83 M outstanding shares. More on Kane Biotech
Kane Biotech [KNBIF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kane Biotech's market, we take the total number of its shares issued and multiply it by Kane Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kane Biotech classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 124.83 M outstanding shares.
Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Kane Biotech Probability Of BankruptcyOwnership AllocationKane Biotech maintains a total of 124.83 Million outstanding shares. Kane Biotech holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kane Ownership Details
About 27.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.03. Kane Biotech last dividend was issued on the 13th of March 2017. The entity had 1:5 split on the 13th of March 2017. Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.The quote for Kane Biotech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Kane Biotech contact Mark AhrensTownsend at 204 453 1301 or learn more at https://kanebiotech.com.
Kane Biotech Investment Alerts
Kane Biotech had very high historical volatility over the last 90 days
Kane Biotech has some characteristics of a very speculative penny stock
Kane Biotech has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 7.12, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kane Biotech has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kane Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Kane Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kane Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kane to invest in growth at high rates of return. When we think about Kane Biotech's use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 1.61 M. Net Loss for the year was (4.6 M) with profit before overhead, payroll, taxes, and interest of 568.44 K.
Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Roughly 27.0% of Kane Biotech outstanding shares are owned by corporate insiders
Kane Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kane Biotech's market, we take the total number of its shares issued and multiply it by Kane Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Kane Profitablity
The company has Profit Margin (PM) of (1.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.72.
Technical Drivers
As of the 30th of January, Kane Biotech secures the Mean Deviation of 2.45, risk adjusted performance of 0.0386, and Downside Deviation of 11.79. Kane Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kane Biotechjensen alpha and the relationship between the value at risk and kurtosis to decide if Kane Biotech is priced some-what accurately, providing market reflects its recent price of 0.0303 per share. As Kane Biotech appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.
The output start index for this execution was zero with a total number of output elements of sixty-one. Kane Biotech Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Kane Biotech price patterns.
Kane Biotech Predictive Daily Indicators
Kane Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kane Biotech pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Kane Biotech's time-series forecasting models are one of many Kane Biotech's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kane Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Our tools can tell you how much better you can do entering a position in Kane Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Portfolio Optimization Now
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Kane Biotech financial ratios help investors to determine whether Kane Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.